Global Recombinant Plasma Protein Therapeutics Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Plasma Protein Therapeutics Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant therapies, rise in awareness about rare disease management and increased focus on investments in rare diseases.
Recombinant Plasma Protein Therapeutics report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Plasma Protein Therapeutics market is projected to reach US$ 136.1 million in 2034, increasing from US$ 92 million in 2022, with the CAGR of 5.8% during the period of 2024 to 2034. Demand from Hemophilia A and Hemophilia B are the major drivers for the industry.
Rising demand from Asia-Pacific region is a major driver for the growth of the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Plasma Protein Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
CSL Limited
Takeda
Octapharma
Novo Nordisk A/S
Pfizer
Bioverativ Therapeutics
Aptevo Therapeutics
Pharming Group
Segment by Type
Recombinant Coagulation Factors
Human C1 Esterase Inhibitor
Hemophilia A
Hemophilia B
Von Willebrand Disease
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Plasma Protein Therapeutics market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Plasma Protein Therapeutics, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Plasma Protein Therapeutics industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Plasma Protein Therapeutics in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Plasma Protein Therapeutics introduction, etc. Recombinant Plasma Protein Therapeutics Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Recombinant Plasma Protein Therapeutics market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Recombinant Plasma Protein Therapeutics report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Plasma Protein Therapeutics market is projected to reach US$ 136.1 million in 2034, increasing from US$ 92 million in 2022, with the CAGR of 5.8% during the period of 2024 to 2034. Demand from Hemophilia A and Hemophilia B are the major drivers for the industry.
Rising demand from Asia-Pacific region is a major driver for the growth of the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Plasma Protein Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
CSL Limited
Takeda
Octapharma
Novo Nordisk A/S
Pfizer
Bioverativ Therapeutics
Aptevo Therapeutics
Pharming Group
Segment by Type
Recombinant Coagulation Factors
Human C1 Esterase Inhibitor
Segment by Application
Hemophilia A
Hemophilia B
Von Willebrand Disease
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Plasma Protein Therapeutics market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Plasma Protein Therapeutics, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Plasma Protein Therapeutics industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Plasma Protein Therapeutics in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Plasma Protein Therapeutics introduction, etc. Recombinant Plasma Protein Therapeutics Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Recombinant Plasma Protein Therapeutics market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices